Frontier Pharma - Small Cell Lung Cancer: Diverse First-in-Class Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease

Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Small Cell Lung Cancer: Executive Summary
2.1 Pipeline Holds Some Potential for the Approval of More Targeted Therapies
2.2 High Levels of First-in-Class Innovation
2.3 Need for Disease-Modifying Pharmacotherapies
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.2 Classification or Staging Systems
4.3 Sustained Innovation in SCLC
4.4 Epidemiology for SCLC
4.5 Overview for Marketed Products
5 Assessment of Pipeline Product Innovation
5.1 Overview
5.2 Pipeline by Stage of Development and Molecule Type
5.3 Pipeline by Molecular Target
5.4 Comparative Distribution of Programs Between SCLC Market and Pipeline by Therapeutic Target Family
5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class
5.5.1 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs
5.6 Ratio of First-in-Class Programs to First-in-Class Molecular Targets Within the Pipeline
6 First-in-Class Molecular Target Evaluation
6.1 Overview
6.2 Pipeline Programs Targeting GTPase KRAS
6.3 Pipeline Programs Targeting Interleukin 2 Receptor Beta and Gamma
6.4 Pipeline Programs Targeting Heat Shock Protein 90
6.5 Pipeline Programs Targeting Serine/Threonine Protein Kinase AKT (AKT1, AKT2, AKT3)
6.6 Pipeline Programs Targeting Hepatitis A Virus Cellular Receptor 2
6.7 Pipeline Programs Targeting Serine/Threonine-Protein Kinase ATR
6.8 Pipeline Programs Targeting Protein Phosphatase 2A
6.9 Pipeline Programs Targeting Histone-lysine N-methyltransferase EZH2
6.10 Pipeline Programs Targeting Lymphocyte Activation Gene 3 Protein
7 Key Players and Deals
7.1 Overview
7.1.1 Allogene Therapeutics Enters into Licensing Agreement with Cellectis
7.1.2 Amgen and MD Anderson Enter Two Collaboration Agreements Across Various Cancer Types
7.1.3 MabVax Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center
8 Appendix
About GlobalData
Contact Us
Disclaimer

List of Tables
Table 1: Definitions Used in TNM Classification and Clinical Staging System in Lung Cancer
Table 2: AJCC Staging of Lung Cancer
Table 3: SCLC Diagnosed Prevalent Cases (N), Thousands, 2014-2024

List of Figures
Figure 1: SCLC, Global Market by Molecular Target and Molecule Type, 2019
Figure 2: SCLC, Global, Pipeline by Stage of Development and Molecule Type, 2019
Figure 3: SCLC, Global, Pipeline by Molecular Target and Stage of Development, 2019
Figure 4: SCLC, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2019
Figure 5: SCLC, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2019
Figure 6: SCLC, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2019
Figure 7: SCLC, Global, Ratio of First-in-Class and Non-First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2019